Company Registration Number- 8013670 The Chanty Registration Number is ". 1147506 Ocular Melanoma UK Report and Accounts 31 March 2025 Ocular Melanoma UK Report and accounts for thè year ended 31 March 2025 Cont•nts Pag• Charlty Inlonnatlon TrvsloM' Annual R•port Statèment ol director•. r•$pon81blll￿*1 Ind*p•ndent Aceount4nt's R•port 12 14 Funds Statements... Staternent of Financial Actmti Statement of Financial Ac1M't￿S- Piior Year stalom•nt Movtrmènls in funds Income and Expenditur• account 16 17 18 19 B4l¥n¢e •h••t Not•• to thg a¢¢ounl• 21 Ocular Melanoma UK Company Regisiiaiion Number- 8013670 Trustees. Annual Report for the year ended 31 Ma￿h 2025 The Trusiees ptestnl Iheii Report *nO Acwunts lor the erwJ¢d 31 2025. Vthch also comprixs the Directorn, Report required b¥ the Compan￿$ Acl 20f&S. R•l•renc• and administrallw d•tall$ Th• ¢h•rftyn•rn•. The ￿9#* name ol the thanty is". Oculw M¢lan(ffia VK. Th• ¢h•Fity 18 4160 kno*•) byits opÉi8iwwJ nump. K4el•nwv IJK. w•¥ioustyOo*l VK {¢W•d Augusi 20241. Th• th•nty ￿ Fooislered in EwLqThJ & Walès wth the Cth￿1ty & W•*$ ICCEWI with chairfy numbeT 11475C6. The th•rity doos not owr•t• th any 0￿￿8$1U￿￿￿om. L•g•l #thi¢lur• olth• ch•r Tho thaiTrty Is consh￿ted as • cory•rrylMnited by 9u•r¥nl••. reg￿l•[8d compl￿e8 Acis. Tho 9OWrning documerf of Ihe ¢h8irty i• th• •nd ArfKlei of A••og•bon •st•t*hThJ lh• comp•ny under company ￿91￿lI￿On. Th• 9o%%rning dowvnl Is dai•d 26 M•ith 2012 Upd8hd Artidès ofAbsooabon •nd SpecJ•l Resolulion 4re d•l•O 20th Au9U512024 Thwe ire M r•sirlL*M8 in do¢wMnli on th• op•r•kn ol th• Ch•rty N on li Sn4*6knèni powers olhw Ih•n Ihoi• imposed by Ch•Dty L•w. By op•r8boD ol •1 Irusiees *rÈ dir•dors und* ITh• Comp•nw Ad 20¢¢ •1 t1ir•dor5 w• Iru•l8•1 und•r Char￿.¢8 ha￿ respons*i1th•5. J$ suf*. uTrJ•r both ¢￿PInY aThJ ¢h•rity*9￿￿tiOn. trUSte•s •r• *1 indi￿￿*. Th• prI￿1p•1 op•r•Vng •Y•r. we tyjr nam• from 0￿￿411 IJK to Or#A•r Mthom• IJK. Th• name ¢h•nge W15 lorm•ty rtg1$ièred on 20 2024 •Tr1 *•5 made lo dirrfy. ensunn9 Ihot Palienl¥. f4mili•s. dinityans and slalehows c•n more •as1ty lewD￿ th• C47nditson w• SUPPOfl. This ch&rMJo supporM our oNJtiiry work lo raise •w•reMJs. Jtr•ryth•n w*r¥t•nth. 8ThJ conned morè p•Wg offected by orJJl*r mdanom• T*ilh lh• 11ghl ￿lOr￿¥bon thnd support W• Ire d8lemln•d to drsNYt Impmwm8nl$ io peoplè can ¥ith mo1￿0M•. Thls tkn b• • dev88181in• uncèr. w wo are 10 •nsure people •cc•6$ lo •lleaib* trèalments •nd Ih•l d•ar Palhw4ys •r• In plau. all v4h￿e >tn¥ryi lo provwjv specwhsi supwt 10 petsp￿ whg need IL Wh•i i• oCu￿r rn•lanom•7 OV￿r m•l*noffl• th • of •yè. - Vve kt)ow approxim•l•ty 750 th• UK ￿•r Ily h•w ••th •rKI Iho8• peoplo are I￿ety lo nee¢J support. . W• know wo pat￿ts in thè VK wth m•lww• t**rt fflgy •diusb"ng 10 life •fler the¥ di•9no¥lB. . We al30 knowlhai one In ewry pe¢•le heaflMyrt•d tr•otrn•nt rfthè ￿l)￿lpre￿d¥ OuJlar melanDma indude$ ¢•nc*rs. u%*•l and conjunctival n*l•rK)m•. u￿81 M￿an0m1 In(￿¢5 tho ir45, t￿tsr￿d or o118ry body. Both types of m•l•noffta can me￿&￿$1&& {w8ad) to 0￿r organs. wilh the Iwof typI￿lty in¥d%*d in 90% of uw81 melanoma ca￿. 11 otular melarM)mo sweads to another or9an. rt 15 curenty i￿rab￿. Som2 tre&trnents ethnd lrfe expfrctoncy and improve qu•lty ol Sle for ￿le p•ti8th. pl￿nIs un f•r* +JiifvAbes OCC*￿￿9 I￿se IrealTri8nts and tlini&*i trials. Ocular r￿aTroma rJ usualy (k5co¥*red dwifvj a examina1￿ or when Ihe P81ient evrien￿3 $ynpl¢ms ènd goe5 to their GP ¢r oplomeirist. optofflebi51 or GP su¥*cts c4neer. I￿Y sho￿￿ up4enVy refei Ihe Pat￿￿1 lo iheti loc•1 Ophlhalrno￿gY departmenl. Shouhl agre8 the rnnr*m. Ihey w41 refer to ￿ ol tow $poi¥ahst ￿￿tres. Glw¢Jw. Lwpool. Sh8ffi8bJ N LoThkn. O¢ular M*lanom• UK Cornpany Re9istrabon Number- lo1￿70 Trustees. Annual Report for the year ended 31 March 2025 Why ￿ (kular IA•l•norn• LIK n••d•d7 peop￿ ￿ ocular rnelaTroma can feel very th. The li ar￿ the pffogn05is often s ovwwhelmfflq Ih81 pat*nls fr¢qtse￿Y repon OaA•r 14olanoma UK abo￿ lo wo4*Je both swpryl •rMI • wic• for IhDse r•r* ￿nC*r. W• brin9 ￿0￿48 i098lher 8¢ro88 thè county and prowde UK.5[￿r￿￿f￿rn•ts"OTh. mel•n¢m• 15 0 rare canw. •nLI pa￿nts 8re Ire¢4uenty oxcknled (wom s￿￿ mdanoma knal$. whith aws rtbèarch Iimiiod ltr* netd for in%*sth)8M wderti4ThJir¥. AS treathwnil propres$. we r•m•in commrtl•d to b•rrws that ptoplÈ from rK•i¥iw kn¢ty and •ppiopn•ie tare. We •1• comThtted to •nsww thot ewry p•tyerrf h•$ wpwl •nd Ii•otrn•nt they In "moty mafinw. Th• rnakn ¢Jnd•rta*•n duthi yJ•i to Iwfvr kn chwtys wrpow for11￿ p￿"¢ b•nefft. Our ilfflj •nd obl•¢¢lv•• 0￿4*[ M•lanoma UK wwde$ 4rwJ nWI￿l¢ll •d¥ic• •nd •LVPOrt thFough varH)uo th•nr*li. P•opkn tel u6 ihey Ih•y had 8btyJt Ilw firsl di•gnoMd. 40 tt*y •psKeci•te ¢h• Inlomaiion and support we provlde. This m8ans • Qrn•l deal to them, so we ha%* plènnèd several pro10￿ 10 Intrea￿ our reach so that once someone 15 diagnoséd. they lÈ*m abOLrt Ocular Melancffl• UK. thè S•Mt&$ prowd•. •nd th•1 * can erKsw•g• w••trn•ni P•ltrM•y¥ to t• tr* ••M th• w•iow•s P•OF4• lace. Ocular Melanoma UK company Registrat￿ Nwthr- 8013670 Trusteos. Annual Reportforthe year ended 31 March 2025 rhe main activities undertaken during the year lo furth•r Ihe ¢haYltys pyry>ose for the publft¢ beneflL To Impvow Support Emoiional & Pracbral Sw)port Our Head of Suppon B supponiw morè PeOK4b and mana9es our ￿ wmmunity Svpport groups. These ive open lo an￿￿ 4ffected by r4nw. w•ekty TheDrwJ¥ prowdo 8 i1f• place lor people to give and recew support W￿1h any diffoJlMS Iheyf8C*. PsythologI￿ Support Conlinued lo provkle members wnh & fvnded profe$wo￿l Support V*ilh * sptrc4ali%l Hèa*h Psychologlsi 10 easé tr05 dia9nos* tan hi%*. This patients Mes throughout th• UK to Jhx fiy*Je¢l w$310￿. Health Infoimati W• m•inlOK￿d PIF ncK •¢u•dilaUon IM Jw8r, m•w* knfcrfm•tion r•t4or* •* • Iru$l¢d 8our¢8. Ow teioui¢*% •r• iévth¥•d by L*tyLaaNS acojricy ond are developed wth pali•ni8. 80 the conlenl ren¢ds *th•l p•oplfr g¢nuiW want •rnl Med to know. W• 10 t￿end the wn¢ttn Informal￿ •¥a#4t4• lo peopl•. Wllh IhE l•unch of ow n•w w•bsrfv. (Y••l¢d • for trusied. (4••r 8nd upio4ai• formation. 11 1$ I￿nged by 1189• to heKI woF4• fvj %th•ithey need wblhoul ft•ling o*nvhokned. Communty Supwt Ai rnenlionod •bob*, w• re9￿81 Mlinè s•38ions for peoF4è 10 tom• wtrthtrr to femow rnd•bon •r faolh•t• pt•r-Itryef SUPWt orfv. W¢ lo ¢•¥elop wr kx•l •mbou•dor wogr•mmo so thal O¢ular Mglanorna UK C¢rnpany Rfrg*trabM Nwrt*r- 8013670 Trustees. Annual Report for the year ended 31 March 2025 Tts Bulld Knowl￿9* Confefence We held 8 ￿trI1•Y ¢MIeren￿, whKh *rywel 4tteTrYqd by patients Ind f•fflty membern. Yel again. wè ad a record nufflbei vl wpltr ¥Jho h•dn'i èlleftd￿ 8 wferen¢e belore. and lor So￿. rt wa6 Ihe first bm¢ they mel 0%￿rS wth the sarne cornlrtjon. which th a huge In itseN. Wa 1150 had many ￿ld1￿ e￿rtS ￿ IhÈir sh•re tr*r kThJ¥Afrdoo Wnh us. en6w•d fv5018lks w• r¢corded and a¥•ilable 8fier Ihe e*ni. so the latest kI￿ge caubj be eastyihared. W•bsite Our n8w web8tt8 va in rts se¢¢nd pha88. c4rw4el•led bery reyivwed. I&￿ing to Pil-Tic* 9ualty 51andard5 and added to our *t•. clin￿*￿ trwls have 81J0 been Iddeo and wdat•d reguiqrfy wllh Ihe upp¢rt of our cl￿1(¥1 Adw¢xy P•MI. Ll3F Melanorna Odober In ￿00•r 2024. we l•unthd O￿tsr Me￿1￿¥ Ch#obv. * c*mw*Jn 10 rait• awartfiois about o¢ul•i mel8nom8 •nd 6UPPOrt 10 those affeded by this i•r¢ canuf. The camp4vJn fealuTed •&￿•110n•t content. communty •￿￿15. c￿Mi￿led in IhE fvsi Otyj￿r Mel•noma 08y on 10 October. marking the charity's 151h •nniK*r%•ry. h res￿•{￿ m • lourti4d Increase In our soci*1 media rtrach and con￿￿&d ihdiwduals n•tyorwh¥e Ihrwh in-person ff￿11￿$. This ts￿$5 Ihe loundglion lor •n •xpinded 8W4r•neM Inili•lN• ￿Or. ¥Jilh blrtady sècuied. OtyJ•i Melanoma Octo￿1 now become an •nNal lo 4rnplity ow rnp•cl •n¢ ¢n¥ur• no oTre lac•s ￿ ffldonoma alone. Jll•tir We Pfo&u¢• • rt9ul•i bLlk*iin lor membern oibYr#J on ow work. lo b•N¢*¥ wi prowde. and, importanlly. infoFm•iitin on how p￿pIe c•n share th811 •Wr￿¢t th us or ded6ion4n8k8r$ to ImwowThnts. AdvoG•cy We cont1rw￿d lo •d¥oc•t• kn p•¥8r41 •Thl l•mkns by ffl•kwy th•ii ￿1¢*¥ th*p• Mllonal con%*rnaiions on e*r•. res••rch and ts4)port. W• contributed p•bènl pvrspvcts*s lo re8••rd% ¥tUd￿￿. en9iged with •nd polwakers to h*JMghl th• i••hl*8 of ooAar m•lanom•. •nd •nsured l¥milN*s w•r• i•w•seffjeO tlesyn Through our ￿1P1￿•. p5yth0￿gicll 1Upp￿ soMt* Ind fonffii. g•thered rea￿￿￿1￿ Ih•l ch4lewe 94p$ In ure and profflot¢ lryroyt¢nents •croM p#itYway. Our •dvoe8cy Ihls yt¥i h•s unttftd M enS￿rI4 woplo ¥cn •ThJ obl•¢lwi. r•wnd 10 •moryJO￿1m. rn•n89• Tho polity proMd•• guid¢kn•s lor I￿ •ppropn•t• of reseNe5. the u¥• •TrJ Inwstrn•nl of le￿￿1. and i¢porfing on reserwi. Th• p¢ty¢y w*1 be It￿ed ar￿u•1Y aTrJ adiusied a8 needed bastd Oculif Mel•noma UK'S fin8nt411 iihmbtin. nsk&. •nd Avall•blllty •nd•d•quKy olass•ts ole•¢h olth• funds Th* board ol tru$l•es ￿ ￿lis￿ed th•1 th• L*•rtVs 86aet6 th ••th fvnd ar• atA48bl8 •ThJ adèqua￿ tti obl*alions In respèct of •ich Ocular M¥lan¢ma UK Company Reg￿tratiOn Number- 6013870 Trustees, Annual Report for the year ended 31 March 2025 Plans For the Futur• Summiry ol pl•n• lof th• l¥tur• •nd ¢h• tru¥t•H' pwsp•¢tfv• olth•fuiw• dlr•¢llon ol th• ch•rhy. We striw to ￿pro￿ thfr ur•. •nd peoF48 receiw. In Ihe ahead, we will our w¢th so thal onc* smieone 15 diagmsed. tt*y ￿8M abtyth OcLd4r Me18nom• UK and tho promdp. and th*1 bt•imeN p•lFrw•ys e¥th* to eas• tho pressures wa know face. We HleniiF*d seTrJeral ways lo red￿ I￿ w*S8ur￿. str•nfftnlw ow ¢*•nty $0 it [• help p￿pIe dnd heir Iaffld￿ Ihiouyh thèse diffKth Iffi)eS. In •ddition ￿ the s•Tri¢ts this W. ￿ wim its1or￿S ow •ffort6 to.. 1. Rtduta del•p In aece$*w I￿OI￿nI lor met•51•tKthx•w •nd 2. Inu••v our Ihai reduc* ise4a0￿ •ThJ ¢tslres¢. W• ￿11 do Ihil by". Improw Support . AHo¥Y P8bènts its book sthtduled c•b 80 they c•n ￿ppo￿ ￿ • th•1 f••lo man•g••bl• for Ihorn. . 8uild • peer.l¢Fpeer nthork 10 5WPWt •TrJ 9uMJ• they p•ii•nts ￿0￿ghOul diagno&ii *nd ty•¥lmenl. - Conlinue lo develop our ¥uhe of p￿1*nI bookleis aftd 184or I￿S iTrform•kn lor ow websit• so woplè c4n •I￿Y find Iiusiod. (t￿vant Inform•tson t*h¢r*¥ef they ntred It. - Invease •warènt81 of d*)it&l th8ls by sharir*J all ￿n￿n slud￿5 on our wébsil•. r•co9niiing Ihal Ih•r8 1$ no olhel 61TrJkn r¢8t)ur¢e brryiro opbons 10gtlhér IDt our tommunty. . Introduce • th•thoi on wr TM•b•l• lo W p•¢*l• find •TrJ wppNt. Pl￿￿J11￿Y of hour•. 8ulld Knv*l•do• . Launch a sumyto ￿de￿I•D￿ 4J•y4&Wy iw¢tolorAlar Mell￿MI on p•opl• •nd Il*irf•mkn•. * m•k• the InsvJh15 widèly av•ilaN• to support unpr0Nw￿nIl m ure ond st￿1¢* desvJn. - L••m from th• eupATI p•¢￿￿1 Expert Tr*iniN4 Proyramme 10 $lrewth•n wr ab*lO c*ntribute mtanirylully 10 re6o•r¢h dilpJui￿ •rwJ •nsw• pai*nt perw¢ty¥w r•m•in c•ntr•l to (ln￿1 d¢dJion mikity. . Atlend key m•eVng¥ in ¢h• IJK •nd •bFo•d. ir*hJdty spe8king •1 t1￿ MY Dlta t￿1•rence. io th• I￿*d expeiience ol o¢ul8t mel•nom• ￿ r¢present¢d wheievèr dtash)Iw ale rn•d•. . RepreseTht our eommuThty atsoss n•Donal 8nd In*M•￿)n11 lorums. NICE, SMC •TrJ NPIS fe¥i•WL¥. 8nd Ihi¢)ugh wr CEO'S ro￿ vmlh EURACAN is ePag lof 10 Ocular Melanoma UK Company Regisii81ion Numbef - 8012670 Trustee$. Annual Report for the year ended 31 March 2025 Dr￿ Resoar¢h . Begin a Kheme lo wport •arty doted￿ ol oc4A*r mt1•r￿. rttww that in the •bsenc* ol a oJre. eartydiagnows Is ore of ihe stron9e$i opportmthes to Sur￿￿1 I￿1 q￿a￿ty01 lrfe. - Conlinue lo Tal￿ awarer*s$ ol Ihtr disease so ptoplè ate diagnosed sooner and h8¥* betler a¢￿8$ 10 limety Irealmenl. - Share rtal-worfd pa1￿￿ knshjht fr¢th s8Thico5. r￿aIr￿S 8TrJ l*nK4•￿ w*r51•nd Ihe thaleng?s Peop￿ fate and ilL¥l￿$ thattruty rÈlIÈGlp*￿t1￿ffiOeds. Be sus18￿1•ble . Expand lh• te•m lo wport OLY ￿ndI￿lIer￿ our HO￿ of M4r*qtsig and to F4*n wo to supwt more peop￿. indudifvJ Ihrouoh ￿1￿911%*$ 8uch 8$ OcL4•r PAel•nomo Oclober. . Entouiagt ffl*mbors 10 shir• h(w our support has hewd thtm. strnn9tr*r*w our commuffj and I￿￿ng oth¢rs lo lundr415¢ or gel Invol¥¢d L8unth an overse•$ th•l￿nge 8*ni in rtspmse to member r•qu•st3. h8ty"r¥J diwrsify In￿me and ItfellglThen ummunilyen9ageffltrni. - Vs¢ all •vailabK• r•$¢urees wsely $0 wr smal te•m 1$ poth.(￿ ￿r* rt r•n have thè W•atsil Impacl. - SIFtnoihen Intem•l prO￿lIeS 8t)d dillrt•l lrtls. th8 IrrtiothKtion ol ow ch•lbol. to ensur• we Femain eir￿en1. responsive aTrJ resthenl as w• grow. E¥eMhing 0¢￿4T M•l8nom8 UK h•s •¢hie%*d toniirn*• to eom• fvom •he•r dedlcakn i p•s8lon to make real th4nge In the livès ol thr￿e 4ffed¢d by IhL4 dreadfrjl cancer. Wo will unbr¥Jo uniiwe h•¥0 a worfd people wth oC￿•r M￿￿Orn• th%*. and Iw w•1. O•tsll¥ of Th• Ind*￿nd+nt Examln•r Tr8￿Y Prflchard BA FCA Ch•rt•r•d Ac￿￿nIan1 255 Povnon Road Wal¥sey Morsoy5kl• CH44 48T 11 Ocular Melanoma UK CL￿PanY Registyaiw P+umber- 8012670 Trustees. Anntsal Report for the year ended 31 March 2025 Stat•m•nt of the Dir•ctorJ Trustsets. R•sponsibiliti•s Th¢ charitys IfU5tee% *r¢ reSpO￿abl1 lorthe y•parabon of •¢t•rdan(* th¢ lerns 01 th• Companies Aci 2006. the chan1￿S Ad 2011 and Ihe Ch•ni*$ IAccounl$ and Reports) R¢9ulaiions 2008. Not<+thitst)diNJ the reqwement in Ihe exlanl slalulory ChanbE% (Accounts and Report$1 Regulabons 2008. to prepare IhE f￿•￿81 siaiements m a￿dance with thtr SORP 2W5. In vhew ol Ihts fact thai Ihe SORP 2005 h8$ been wrftidr￿. Ihe Trusietrs dewmined lo Inlerprel Ihr4 responsbility 88 r•quring them lo folLw rJmTIt besi Pl8Clice 8nd prepare •c£oun15 •ceordtn9 lo the FRS 107 SORP Islatemeni of Recornrftnded PracbEe fN A(￿Untir*j ¥rwJ Reporbty bychanbesl 2015. (as am•nded by th• Bulelin issued in o&ob•i 2018 and •pWK•ble lo 4 •ccounbng penods orb ry after 1s1 J*nuary 20191, lThe SORPI, In partKutsr. Ihe Compan￿8 Atl 20C6 •nd th•nty 18w r•wir• the Boafd of Tws1￿5 w prepare finanual $wtemenis for each fvwnu•l ￿¥r give a ar￿ of the $18to ol •ftair5 01 as ai th Ind ol fkn•n¢ial •nO of ihe surplus or olV* ch*rty. In pwpwitw Ihose fin•nc4al statements lh• B041d 1¢ r•quired lo ' pr¢pirt *ctsunis in 8¢¢Otd•nce with Unlled KK4dorn Genera* Accepted Accounliw Pi•cbce litr*t¢d Kirydcrfn Acco￿￿)9 siand•rd$ •TrJ law}. . ￿1￿cl suilitdè act0￿￿ pokw8 ond applytsm conwttrtty. - m•ke hJdg•mènl• •r*d e$lim•l•$ Ih•t •re rfr•sonablE Ind w￿￿nI.. . prepaie Ihe finorKi•l ¥l•l•m•nts on ts going eont4m basrf ￿•$5 il ts kn•pproprfil to pr•iume Ih•l Ihe thinty ￿ Contir￿a in busms$'. &i*t• whèih•r applic•ble •¢ctyJnlirvJ ilandarfs st•l•m•nts ol recommended praeltce how b••n fol0￿. *￿Je& t• any •J•partw•s •rwJ •xptslr￿d ￿ lh• T￿ l•w rtquir•s Ih81 th• tyustse$ mu51 nol •pprow I￿ urths they we ihal Imy gi¥* Irue Ind l•ir ollh• st•k of all•irn ol Ihe ¢h¥iityand of th• xxphjs or d•fKrt of thè tharrfy lor tho y*•r. Th¢ Trusl•e% ar• also r*spon*b￿ lor ma￿181￿n9 •deqvat¢ 4ccouniing ￿¢0￿5 t*hkh dlsdose wilh r•asorSab￿ •CCUfa¢y Ot •ny trml kne finanail pos*bM of the (hanty ond suffic*￿ io show and •xpLgin ch8ri1¥8 tr•n$•thons and •n•ble lo enswé Ihii the fina￿]•1 $tslerr¢nts compty wsth Ih COMp4n￿$ Acl 21)08 and Comply ¥Mlh rey￿allOnS m•d• unaer the ChaIrt￿l Aci. TF*y 81e •l$o re5pon51ty1e for $4fegu•rdiw the •$5•1s oi the r*nt* lor rn•irmb* sbps for the prt¥•￿On *fvJ d*￿Cli0n of •nd olhw thLl81ths. The TnMleeB or• •150 r•spon*le fN Ihe conlentl ol the TnAte•$' ff•port. •rbJ Ihe #lalulory re8pon6iblhy of Ihè Independènt Examk)•r fft relalton lo Tw$le•s' itporf its Imited 10 examlnwy lh• report and tnsunrvJ th•1, on Ihe 14¢¢ 01 the report. ther* *r• no matèrial ¥nth the fffjures di8dos8d In I￿ finonry•l 12 Ocular M•l•n•ma UK Cthmpany FQe9BI￿*Jn N￿L*f-Bot3610 Trustees. Annval R¢port lor th¢ year ¢nd•d 31 M•r¢h 2025 M•thod of pr•p•rntlafi ol ao•ounts - Sm•ll •omp•ny pr•vlslons Th• financ￿$ 1ts1oments arn on p•gH 16 to 35. The fnancs•l slalemtrnh h&￿ bèèn woporEd wnp*rthrvJ FRS 102 SORP Ists*m•nt of R•comrnend•d Prarlw Athwnl*bg and R•porfry by ch4nt￿l 2015. (• *n•nd•d by lh• BuM•tln issued in October 2018 and appllt4b* lo •1 ￿t￿nbr¥I pEr￿S Winnir*J on c¢ aftei 1S1 January 20191. (Th• SCIIPI, and kn •ccthirK• Repffii 102. l•fknthe 111 Jwu•ry 20161 Compan￿* ALI •ppk*bltr lov)nwNlS Sutyd to th• *m•l r•0 MRS C EOWNIDS Dii•G*r •nd Trnth• 13 Ocular Melanoma UK Report of the Independent Examiner ¢0 the Tn￿te￿ olthe ¢harrlabl* ¢ompany on th• *c¢ounts lor the year ended 31 March 2025 I repDrf lo the TfUStee5 on ry exarninalion of I1￿ finanr}￿ slalemeThis of Iht thartablt tompany on pages 16 10 35 for Ihe year ended 31 March 2025 *thich have been prepared Iri aCtL¥dar￿ wlh IhÈ Charthes Aci 2011 (the Acii and ¥%ilh Ihe Finanpal Reportsry Slandar(1 102. (ellects￿ 151 Jarxjary 20161 as fflLKlified by FRS 102 SORP Islalemenl of Recornrnendett Pracbce lor Accowlmg •nd Rewtin9 by Charthsl 2015. las ameThJed by Ihe PuHetsn issued In October 2018 and appk¥bk to a# accwnbrwJ peviods btguKuTrJ an or after 1$1 J8nuary 20191. (The SORPI, published by the Chanty Commission in Engtjrwl & Wa￿5 ICCEWI . •nd undÈi the hisloncal cosi ¢Mveniion afid accounliry pOlK￿ Sel page 21. R•sp•Gtlv• T•sponslbllitl•* ol th• TnMt•ts •nd th• Ind•p•nd•n¢ Examinv•nd th• olth• rnptsrt As dèstribed on page 12, yw. Ihe tharrtabk corwanls TrusieeÈ. Trhtho are al&0 D*e£l￿8 ol the Comp8ny lor the purposès ol Compary law, are re¥￿r￿ble for ts prepzT*tth of Ihe financial st•iemeffl8 in accordance %￿h th6 Companie5 Act 20(N8, the Chanl*s Ad 2011 and all olher applicab￿ arwj ¥Mth Unrted Kingdom Generally AttepiÉ4 Actouniiry Pract￿. •ppk•blp lo ￿)ller eribW. lor ublfied Ihe th￿C4a1 sialemenli ivt a Iwe And flir vw. The Tntsle•8 eonsider Ihal Ihe audrt reqLriremtni ol Seclth 144111 of the Ch8nthe8 2011 Ilhe Acl) does nol apply, and Ihal there is no requi10N￿￿ in Ihe ff*mNandtsm •TrJ artK*$ ol Ihe tharty for the crrtucliThJ of an JLKJit. 8rKI thal the accotsni8 ¢Jo require an a￿11[ In ac¢yNdance Part 16 01 Ihe cCffjpan￿S Acl 2006 and Ihal no member or membeis have requesied an a￿111 pwsuarn 10 Section 476 of the Companie5 kl 2006. As con8tqu8nce. Ihe Tru81ees have elecled Ihal the finarthl ¥laten*nts be S￿)10¢t lo indepondenl IX￿1r￿￿n. HaV￿g sali¥fied my5dl Ihal Ibe slalements •r• I￿¢ requirtd lo be LMNler •Ny *g•l yovision. or olherY+i¥e, •nd are el￿1b10 for indewndenl eufflmalw. it io my rewnsknthty lo- •) ¢x•mine rinanoal 31ilemenl$ of th¢ ch4rfy w¥Jef St￿￿ 145 of Il* A¢i.' bl fol￿W1he applicable p¢o(*dwes in the w¥en by b)e Charity CofffflM2•)n undw 14515llbl of the Ad. 81814 of I1￿0P•￿￿•fit Ex•mln•fs St•t•m•nt •nd ￿0p* of wtyk und•rt•k•n I r•p¢)rf kn re•pecl of my exarniMbon ol 114ry si•i*nwis t•rrtl fAI 1145 ￿ th¢ A¢1. In Corrying out rny eyaminalicffj. I haw folml all the applKaNe t*rediw5 given by the Ch•nty Comffliision under seclion 1451Sllbl of Acl 3eitsThJ out the ¢JU1￿ ol an ￿deper￿JenI examinEr In relation to t￿￿U￿1￿j ol an dependenl examinalion. Ind•p¢ndenl examin8lH)n Indthles a revwi of the •ccounlirvJ records ke￿ by Ihe ¢haritab￿ ¢¢)mpany and ol 1cco￿tIng Sy51em$ employed by Ihe L*arf8b￿ tompany and a tomp8ri$0n of Ihe finantial ¥i•iemtnis PTe5enled wlh Iho¥e recwds l also mdLKlts u)n8Klerai1￿) ol any unusu&l rtems oi dist4osure8 in the financial siaiemenis. •nd sèekty èW*n•lK)ns from you. as Tntsiees. conL*niNa iuth matters. Tho purpose ol ihe examinaiio¢i Is lo esiabh'sh •5 lar as possible Ihal I￿re have been no breache8 of t*aMy *gi￿atsOn and thal, on a lest ba818 of eyldento rdev*nt to Ihe m•Je. the rm8￿1•1 si•ten*nl8 cornpty %•lh the SORP. The Pfocedures ￿0ertakefi do noi wovmle am the evhJenc* Ihal te rnqwred in an audil, and ￿1r￿li Supplied by the TNstee$ In Ihe ctyjrse of the examin•th￿ Is nol S￿0￿ lo audd tes15 or enouiries grKI doe5 riot cover ill Ihe matters that an audrtor cmsider wi afriwThJ al an opin￿. The d•nr*4 •fvJ f•>xl￿1 of •n •udit goes boyond Ihe Iimrfed 888urance that an i￿nden1 exami￿￿On can Consequerilty, I do not ewess arb awjit op¥rAon I1￿ by ts finawl $tat¢menlJ, and kn partirxdar, I Èxyes& no opirmon 8$ 10 *thelher Ihe finantial statements give a and la* view ol ol Ihe c*arty. and my report is limited lo the matters s*1 Oth In lh2 stjternenl be￿. l F4anned and performed my examiThabon 80 as lo sabsfy myself that the ¢)b￿a￿e5 of fv irKIBpethnl ex8rnin$ ore atheved aTrd before report l oblaimd willen 8sxv•ncesfrom fv Trustees of•1 mattern. 14 Ocular Molanoma UK Indop•nd•nt Examln•rf* StIt•rn•llL R•port and Op4nlon SL*)ieLt 10 h"mrt¥D￿ IhÈ sccye of my as del8led above. I ha¥e compleled my exarninabon". and Can confimi that".- The accwnts trf thorilaNE comp•rw ire req￿red to be a￿lite￿ thjer Part 16 of Ihe Comparmes Acl 2LX16.. This & rnport ￿ respeca ol an eXam￿al￿)n tyjl urkjtr 145 of kl arKI vAth I)￿1￿$ gwen by Charty ComnNSSKffj under Sec1￿ 145(5llbl of the Acl th may be awAicabl¢. *￿1 that no moienal matt*rs hav¢ c4)me to my *tteniitin ￿ C￿e￿O￿ with Ihe eXa￿￿allOn rrh7 c4use lo believe thal In )ny maiefial fesped- a¢couniin9 retords ￿re not *epi ￿ resped olthe d*nty as by Seckn 366 0111% com￿n￿ Ac¢ 2006 aThJ Section 130 of The Ch8111*8 Aca 2011.. Ihe fnanual slaternnls do nol accord Ihose rer4Yds. the finanual 8lalewl8 do rK¢l corry*y %wih applicatrAe rewyemtyms the lonn tiJnt¢nt ol accounls Sel oul In sectiw 3% 01 Companies Act otrr Ih•n •ny re4uir¢m¢M Ih•t the aL%ounli gfve • 8TrJ farf view. *ttich 18 nol a rn•tter conshyered •$ part of •n mdÈpÈndeni eximinal1ts1. howe nol been pr•pwtd In accwdance Mith ￿￿th0o¥ oul in Ihe FRS 102 SOAP Islalemenl of Re¢ommeTrled Prathce forAccowlry and Repprtffj by Ch#iii*sI 2015. las amended by the Bullebn issued in Oclober 2018 and JpplKable lo •ll JGCthmliNJ w*)ds bÈgiMlry on LV aft•r 181 J8nu8ry 20191. (The SORPI. I haw no corTrcems and hove arJoM ￿ 011￿r m•llers in ¢¢w*¢tion vAh lh• •x•mination to attenlion Bhould be drabw in this reporf In order to enat4e • proper undws1•￿lry of Ihe fin•ntiil siatem•nls lo reached. Tra￿Y Pritth•rd BA FCA- Indep•nd•nt Ex•rri Ch•ffltrnd A¢¢4miwi 255 Foull¢n Ro•d W•llaBey Merney8h16 CH44 4BT This report was 8yne¢l on 12 202S 15 Ocular Melanoma UK - Statement of Financial Activities for Ihe year endod 31 March 2025 Statement of Financial Activities (including the Income and Expenditure Account lor the year ended 31 March 2025. as rgquirod by the Companies Act 2006) Cutt•nt y•ai CuM•nty•ar Current ye41 Tot41 Fvnd p￿Or Ye4f Totsl Fund¥ Fun Fundb 202$ 292$ 2024 Incomo & Endo*Tr•rrt¥ fr¢Jm: Donations & Lega¢i•s Chariiable a¢tMfves Other tr•ding •¢11￿•$ I￿￿¥1mentI A1 69.884 126.1fj6 247 sJ.sJi 939 103,133 325 45,317 520 247 53.531 Total In¢om• 09.W 180,903 149.29$ Exp•n¢uiur• on: Railing fvnd• Chaiitabk octNrtieJ 81 B2 1.777 1U,684 2.972 147.011 67.101 79.583 Total ¢xpendlturo .878 79,583 173.461 149,983 N•t Incom• lor th• y•ar 19.6991 7.442 16881 TraMf•rn b•twwn lunth N•t In¢tyn• •ft•r tra￿1•19 17.141 1#.$991 7,442 16881 Net mov•ffl•nt In lurK 17,141 19.6991 7.442 16881 R•conclllatlon of lunds:. Toial funds brought forw•rd 41.408 36.607 n.015 78.7tyJ Toi•l funds urrl•d ltywwd 58,549 85.4S7 78.015 The 'SORP Ref indicated above ￿ Ihe cla5sificakn of incoff* sel out In lh• frrnal SORP documfrnts. As requirtd by paragraph 4.60 of t￿ SORP, the br¢u9hl f¢rwar¢ aThJ carrnd forword lufvjs at>J¥e ha¥e been 4raed lo Ihe Balance Sheel. A separate StaternMI of Totsl Rects3nkMd G•Th Losses 15 Th)t rn4LHrtI •$ this $t•tement In¢1￿ •ll recogni8ed 98ins and losse$. AJI actiwlie8 deri¥e frcffl conbnuiThJ OFeratior Thè not•s attach•d on pag•s 21 to 35 torni an Int•grdl part ofthese accounts. 16 Ocular Melanoma UK - Statement ol Financial Activities for the year ended 31 March 2025 Ocular Melanoma UK - Anatysls of prlor year total funds. as requlred by paragraph 4.2 of the SORP PwlorY••v PwlorY•ar Y••t SORP lknwtttrict•d R••triGl•d Totsi 2024 2024 2024 In¢om• & Endown•rts irtyTr'. Donat￿￿# & L•ga¢K•$ Charrtab￿ 8etwrt Olhtrr If•Jin9 a¢la'w*es In¥*strnents A1 42.133 325 45.317 61.ocri 103.133 325 45.317 $20 Tol•1 In¢om• 88.295 61.CQJ 149.296 Exp•ndllur• on.. Raising funds chafilabk a¢livili¢• Bl 82 2.972 2,972 147,011 58.211 Total •xp•ndtur• gJ.772 66,211 149,983 Net goin• ￿ In¥e8lments Net Incom• for the y••r 15.477) 4.789 18861 Transf•rn b•lwe•n fund* N•t In¢om• •ft•r tr*nsf•rn 15.4771 4.789 Net movement In lundB 15.4771 4.789 RKon¢lll•tlon of lund4'.. Tot•1 fund8 brought lo￿ard $4.910 23.793 70,703 Tot￿ fundB Ufrf•d forward 49.433 28,582 78.015 17 Ocular Melanoma UK - Stalement of Financial Actlvlties for the year ended 31 March 2025 Ocular Melanoma UK- Resources applled In the year ended 31 March 2025 towards fixod assets for Chaflty use:. 2025 24 Fund$ genorated In the y8ai as d8tail8d In tt* SOFA R¢8ource8 applN8d on lunthonal fixed a65•ti Olhei applications of lunds 7.442 16881 N•t rè8oure•s avail•bl• to lund ch•fftabl• •¢tfvlll•¥ 7,442 688 Th• mswr¢•8 ors fix•d ¥is¢M ￿ ehanty fepr•s•nlS Iho cosl ol •Jdi*on¥1885 proc•eds of any di$po$als. Th• not•s attach•d on p•g•• 21 to 35 lomi •n Int•grnl part of th•￿ accounts. Mov•ments In revenue and capttal funds for the year ended 31 March 2025 R•v•nu• accumulatod funds UnrnAirfcl•d Fun R••trkt•d Fuhd* 2026 Tolal Fund• 201$ L4•t ymr Totsl Fvnd• 2024 2025 ulat•d funds bro￿h1 ltyw4r(I 41.406 36.607 78,015 78,703 R•¢ooni$ed 9olrr4 •nd th8•$ b•for• transfors 17.141 9.6991 7,442 16881 SB.$49 J8.467 78,016 IFromirro unrtttrithd r•venu• fu clo￿n9 I•V•n￿ lund• S8,$49 26,908 15,4S7 78,015 Summary of lund• Unv••lrl¢t•d R•*trtci•d To1•1 Fund• Fundl Tot41 Fund DM*n•l•d luthd• 2025 202S Z024 Revenue accumu￿1•￿ fvnd$ 58.549 85,457 78.015 Th• notss atlached on page• 21 to 35 fomi an Int•gral part ofthese a¢¢ounts. 18 Ocular Melanoma UK- Statemenl of Financ•al Activities for the year ended 31 March 202S Ocular Melanoma UK Income and Expenditure Account for the year ended 31 March 2025 as requlred by the Companies Act 2006 202S 2024 In¢tW> In¢ome frw Inv¢$tmgnt incor Inlere$l TO￿1¥ab 179,964 148,775 939 520 Grlxs Incom• In th• year t>•for• •XC•P¢lobW knms 180,903 149.295 Gro•• Incom• In the yur Includn9 •X¢Wlond tt•rn¥ 180.903 149.295 Charilabkn exp•nditur•. •x¢￿'r9 dey•cwbon aThJ arncrfl5a￿rt Oeprecialion and amorfrs•bon Fundra151ng CO$1$ Gowrnanc• co$li 165,318 142 ,777 1,224 145,598 243 2.972 Totsl expendI￿rn In tho y••r 173,461 149.983 N•t Incom• b•lor• t•x In th• finarKlal ye*r 7.442 16891 Tax on surplu• on ¥¢lMb N•1 Incom• •ft•r tax In th• Ilnanc141 y•ar 7.442 18881 Retsln•d surplus for th• fin•ncl•l y•*r 7,442 All a¢liMties d•rive from contsnuing oper•tw)n8 In accordanc8 Wrth lh• pr￿S￿)n$ oflhe ¢¢ryan*s 2fX6. thfr heathws s￿)head1￿3 us•d in ￿ Ir￿￿ and Eypendilur• 0¢￿Unt have been adapted lo refiect special natu￿ of t￿ chaiitys acliwbes. Th• note• 4tt•¢h•d on pagm 21 to 35 fomi an Integr•l part ol th•s• accoun1¥. 19 Otsul•r M•hnoTD• UK- B•l•n4• Shoe* •s •t 31 IA•f•h 2025 SORP NotCR Z025 2024 Flx•d Au•ts a*￿tS 10 238 2.11)J 12 82 22.W 59.027 77273 7.1¥7 79.381 1.731 5.>31 78,015 Th• l•l•l I￿1 i•••i• •1 **•h•rfty ¥•funaDd bylh•fvndB ￿th• •h•1￿. M l#11￿... 17 DI 36.607 38,IM7 Unr•strl*d F￿dI 17 03 S8,$4• Taiil •ttwlty fv ha¥Y bv•n •or•¢d lo Ihv SOFA underw¢trM 477 01 Comp*nM Act 2 Th• m•mb•rn n¢1 l•q￿r•d thè ctympany io Obts￿ •n •ytht 476 Ex4mmf* ￿ p•a• 15. 20C¢ ippIca￿#t0 *ubJ•¢l lofv r£thp•n*s regmht Ocular Melanoma UK Notes to the Accounts for the year ended 31 March 2025 1 Aeeounting pollcl•8 Pollclés reladng to the pmduetlon olthe accounts. Basls of preparntlon and •¢cow￿￿9 conv•nllon Th? accounts have been prepared cffj the accruaL% ba$$. unthr the hi$iorical cost Con¥ent￿n, aTrJ In accrxdance with Ihe Financial Reportln9 Slandaid 102. leifec*¥e 1st Jar*uary 20161 aTrJ 'FRS 102 SORP Istalerwii of Rerxjmmended Practice for A¢¢ountin9 and Reportsng by cha￿lIes1 2015. las amended by the Bulklin ISSL*d In October 2018 and applicabk8 to all accounbn9 pef￿d5 be9inniNJ on or 8fter 1st January 20191, (The SORPI. published by the Ch&rity Cwmis$i¢n In England & Wa￿S IC¢EWI . effeth¥e January 2016. and In ac￿rIan¢< with am applicable law In the charty's jurisdiction of reg151ratw, except Ihal Ihe ¢hanty h•s ￿p8re￿ the financial statements In ac¢ordan¢e witti Ihe FRS 102 SORP Islaiemenl of RecommeThJ¢d Pracb¢e foi AwJunbThJ and Reporfin9 by Ch•nlie$l X115, 14$ omeTrJod by Ihe BUl￿tin Issued In October 2018 and applKable lo al accounbryj per￿S tegiMlThJ on or after 1st January 20191.1Th• SORPI, in prefertrn￿ to the pr•vtsJ$ SORP. the SORP 2C#)S. whKh has b8en wthdrawn. nO￿l￿Standing the fact Ihot Ihe exlAnl $l&lulory regulation5. the Charit￿5 (Accounts Reports) R¢9u*bOn$ 2008 reler explialty to Ihe SORP 2005. Thi5 ha5 been doro to acctyd wilh ¢urnent besi kwacD¢•. Rlsks futur• •uumoioM The charity Is a pubtK be￿fil enlty. The Managtrnenl Commrtt•¢ has r•¥**ed the mw to wl¥ch fv charity h•$ expo￿￿. Wher• appropria￿, •ysl8rn8 or piocedure5 have t4en e518￿1&h•d lo mil*Jaie the risks Ihe ¢hanty face8. Oui Regional Representatw￿ 4¢0 e¥¢h IS$￿ wrth Ihe O¢LAar Melanoma UK RepFe58nl•ti¥• Handbook and •re Invited lo 8ttend a troining ses810n. Flnand41 conlrd Mki •r• minimrned ty 01 prrx*dure8 kn authwisalion of all tr4ns•ctK*ns. Accountlng for del•fr•d Incom• •nd lrtam• f•¢•lv•d In •dv•n Where Iwm• •nd C£￿dI￿"0n￿ relalmg lo ir￿Orr* hav• T￿1 b••n rn•t or unurt*nty t￿•￿ u to whother thv charity can m•oi any terms or condifr'ons Oth0￿1$• wilhin its cmlrol. Inccffi• 1$ not wnrd8d but M thf•rnd al • li•bility until Il 1$ VObab￿ Ih4t t￿ l¢rms u ¢ondrt￿ns 4np05ed can be met Any grant that IS 6￿jj•￿ to wrfomi•r**-r•L410d W￿l￿on6 r￿￿ed ITr thancè of dolN•riw the 9ood$ •nd servi require¢ by Ihal condition. or Is subjecl lo unff*l col*J￿0￿$ wholy outsth the ¢gntrol d the r0¢y￿1 charity. is accounled lor 8S 8 liability and th• bal•nc* $lwt as deferred Incorne. Deferred Incc¢M ts r•￿¥6•Y 10 income In Ihe r•p¢rtirs por￿￿ In whi¢h wrfom)On¢￿e1a1ed or olhw cor*Jrtws Ihat Iimil recognfyon I￿ rrnl. When In¢ome from 8 grant LY donalion has not bo•ft r•wn15•d due 10 the conditions applyiThJ lo th• not t•iNJ whol wilhin the Control ol th• r•¢iwnl ¢h•tsty. rt f4 do¢losed as • ¢wtireent 88501 if r•¢•ry)l of 9rwl or don8bon 1$ prob4bl? on¢¢ those ¢oThJitsons are Thl. Wh•m tirn• r•lated ¢wdrtion$ We ryos¢d or mphed ty a funder. Ih8n the irbctyn• 1$ •pptyty"oned lo the time periods concer￿. and. where applKable, is xwjnled for as a Iiabslity and $hvAfn on the balanee sh*1 a5 defvrred income. When grants are rt¢eNed In athfan¢e ol Ihe exFeThJrture on the acti¥ity funded by them. bul rhe￿ are no $pe¢ifi¢ lime related cDndi*'on6, Ihen Ihe is rKst dela￿d. Any condition that allows lor the re¢tyery by Ihe dorKv of any uneyr¥Jed part tsf 3 grant doo$ not pre%*nt r￿n￿10Th of the Income concerned. but a labikty to any repayrnent Y4 recogn15ed wl*n repaymenl tecomes probab*. 21 Ocular Melanoma UK Notes to the Accounts for the year ended 31 March 2025 Donated goods. facilili•s and s•Thflces Donated assets are recogn*ed at Ihe ¢wrent fwr tAlue. Al suth donabJn5 ar• ret¢9fi￿ as donation irKcrne. 8nd debited lo fixed a55el5. Donated 9¢ods that are nDt fjxe(l assets ar¢ occounled lor 4t a lair v8lL*. un*5S mwro¢tical lo reliably Measu￿ tho value of the donated items. In Ihe absence of any direct evvJerK• of fair Val￿ of dmaled goc#Js, a valtse ￿ defjved from the cost of Ihe 1￿M to Ihe donor or. in the tas• •19oods thot ar• expeclod to be sobJ. th• as￿rnated fesale Val￿ after deduc*ng any antr¢ipated costs of Sa￿#. If il 1$ imwactscabk lo measure fair value ol gr*Jds donated fty resa*. or fv co$is of valua￿on outsveyh the be￿rit$, the donated good$ are re￿nised a5 Income wl*n $old. wrth an equr¥aleni ¥fioiir*l being reco9ni$ed as an ex￿nse. The ¢o$i$ ol goods donaled for di$iribvbon to ter*fKlar￿ Is to be the lair value of Ihose goods upon ￿ceipt When Ihe goods are di$iributed Ireely or for a n¢min•l ¢on$Kleration. Ihen It* ¢affying amount is adiu$ted at the time of sale. 10 th• value at point of distr[t￿kn •r¥J the 8diu51ment IS 5hMI a$ o cost of donabon$ mod¢. The carryin9 ¥m¢unl ol any 51rtk hokl lor assessed ftyr iffyirnwnl al the date. AJI donated goods •r¢ recogniwl as donation Irwme, debsted to tradin9 stock. When trathw $lock sub$equenlly $oh#. or appropriat•d to meel an expens•, then Ihe car￿￿j value of Ihe 51rtk r¢cognwd as an expense. In accordance with the SORP, gotrjs donated for th$int￿tran to beTh8kiaMs. ¢onsumFI￿n by IP* chonty are ¢n¢hJd•d ifi'lega¢i¢s and donations.. Good$ dw4led for resalB ar• inCK￿d 1n.1rK￿￿ frcffl Ir•dity gcti¥itie5' The ￿1 of any $lock ol good5 dortat•d ft*r ¢JBlribulvJn lo beneficiar*$ ¢ deemed lo b• Ihe 18ir value of Ih05e gffts al th¢ Ilm¢ ol their receipt. If 9¢ods ￿k1 are lo be dislributed oi for a nr*fiin•l Co￿lderat￿1n, Ih•n IN* Carrying amount 18 subs8quenUy 8diu$ted lo refiecl lh• Imr ol d¢¢fi￿ c051 fvr h)ss 01 Serw￿ potential and re￿aceMent cost Replacement c051 1$ ihe e¢oncffjic c051 incurred rf the ¢h•nty was lo r•plxt thg service potential of the donated goods at tts rw4n txpenw In the most ecofiomK m*n•r. Oonaiod $•rvic*6 and faalrt*s lincludiNJ s•cl￿ed Siaft aTra w ol pryrtyl are indvoed in tts occounts on th• basil ol the valw of the gift to ¢hanty. AJI donat•d and faclities are r•cogNised as donation Inccrn when rK•Md. Iproythd th¢ of the 9Tr7 Gan measured reliabtyl aTrJ ie¢o9ni$ed as an expen58 an equiv¥knnl valu8. Poll¢l•s r•lallng lo •$$•ts, Ilabllltl•s •ndpmvl*lons •ndolh•r m¥tteTS. T•nglbl• Ilx•d•ssrfs Tan91b￿ fixed assels ar• measured al ￿1r orynal cosi valuo. or subsequBnt rtvaKJ•i￿. or rf d¢)nat•d. M d•s¢ribed ¥bo¥e. Cost valu• ijcludes am costs eyr%Jod ith bnr4irg the asset Into 11$ In*nded woFkirvJ c0fvalt￿n D¢precialion has been ProWd￿ al the fc4kMing I•1￿ in or(l¥ lo ￿11• ofl its •s•ets lo inii¢W•lgd va￿* Ovor th•ir Mtim•l¢d Lpjefil lfft8. Plant and machir ¢Y*W 3 y••rs A regulAr annual rtivi￿ d Ihè likelihorx1 of as￿1 mp•wnwnt • undertaken. Stock¥ and work In progr8S$ Slo¢k Is valued at Ihe lower of ¢o8t and [￿1 r•alk%•b* val￿. Fund AccountSng Un￿stnCted funds art for use at +Jis(yebon of the tru5*•S in ILwlherance ol th? 9•neral o*ctNe8 ol th• Charty. There are no end¢xmenl fijnds. Ocular Melanoma UK Notes to the Accounts for the yeai ended 31 m?￿h 202S 2 Liabi5ity lo tsxation The Trustees consthr that the tharity $ab"sf￿S Ihe tests Set (￿rt in P¥a9raph I Scheduk 6 of the Finance Act 2010 for UK corporation tax purposes. ACC￿d1￿Jty. the Chanty ts $￿entIo1￿ exempl Irorn wty¢n In iespecl of income Of capiial gains [?￿Ned within catego￿S covered by chapter 3 part 11 ol It￿ corporat￿ Tax Act 2010 or Secbon 256 ef the Taxation ol ChaTge#ble Gains Act 1992, to the extenl Ihai such income or gain5 are appl￿ exclusively on the specific Charitable oty¢¢ls of Ihe charity aTrJ for no other purpose. V￿ue AAded Tax s not reco¥*rable by the chanty. and 1$ Iherefere Included in Its re￿¥￿1 ¢o$ls in Ihe Stalemenl of Finanty¥l Acts￿￿5. 3 Winding up ¢1 dl8$olutSon of th• charity If upon winding up or dissoluiion of It* charty the￿ remain any 8$sels. after Il* S¥li$fa¢tson ol 811 debts aTrJ liabilitie5, ItK* ¥$sets iepffjs*nted by Ihe accwnulaled lund sh•ll t• translerred to soD* Olhw ¢h•ritable bc#Jy or bad￿$ hawn9 $imilar objects lo the chanty. 4 Slgn5fKanc• of fln•n¢lo1 Instrum•nts to th• charity• pts¥1￿0n There are no $vJnrficanl ImF4lcat￿nS of such matters 5 N•t surplus ￿lorn lax in th• fin4nGi•l 2025 2024 Th¢ nel Su￿Ul belor• lax In finanual y•ar ￿ stated aftw charg1ry.'- D•we¢i•iion 01 ft¥ed 855•ts P•rAion ¢￿ts 142 2.429 243 3,888 $ Staff costs and •molum•nts S•l•ry ¢osts 2025 2024 Gr￿6 Salari￿ *￿￿￿jir9 tru8lee5 and kty mio•g•m•nt pmon￿l Employ•r'$ operalin9 ￿$ts of defined ¢onlr*ulion pen5Kn $¢h•mes 82.885 97,851 2.429 3,888 Total sala￿￿. wagm •nd r•l•t•d ¢o•ts 85.314 101,737 The 8¥erage numter of full lime stalf employed in the year was The e51im8tod full equivalent numier ol $iaff eftwSoyed In Ihe y•ar w•• Th• eSiim•i•d•qulval•nl numb•rof fvll tlm• ¢l¢plo>Ydln dffW•nt•d•￿11•S In tho ywr w*s.". Effja9ed on ¢hOrrtab￿ actMI*S Th• *Sllm•i•diull Ilfft• •quiv•lthtnumb•r 01￿1 stsff wTrployed*s •bo¥• Neither the trustees nor any perw$ cmnecled t*th Ihem ba%* rece￿ any ￿l￿ra110n fr￿ Ihe ¢hanty or any relaled •niity, either in the curnent or prnr yèar. No employees re￿1¥¢d emrluments lexduding ¢ost&l in ex￿5 of£60.Lf#) per •nnurn. 7 Defined contribution penslon sch•m•s Any118bilile8 and asse15 a5$0cialed with the scheme are shrth￿ urth debtus aTrJ credilors. 23 Ocular Melanoma UK Notes to the Accounts for the year ended 31 March 2025 B R•mun•ratton and payments to Trusteès and pèr50ns conn•ct•d with them 2025 2024 R•tyun•r•lionp•￿1o t¢+ or conn•d•épwsons No Irustres or ¢onne¢ted persons re¢eW remMira*"or 9 Trust•8s' •xp•ns•s No twslee expenses were incwred. oither in Ihe cwrenl or hwr. 10 Tangible fix•d as8•ts Curr•nl Y••r Land and 8ullthng6 Pl•rt & IAachlnery Motor Vehlcles Total Cost At l ￿ri1 2024 Addilior 3.552 3.552 At 31 M•r¢h 2025 3.SS2 3,6S2 D•pr•clallon At 1 April 2024 Chafge for the year 3.314 142 3,314 142 At 31 M•r¢h 2025 3.458 3.458 N•t book v•lu• At 31 M•reh 2025 98 At 31 M•r¢h 2024 231 238 Prlor Ymr L•nd •nd Bulldlngs pbrt& MacNrnry Motor Vehlcle¥ Tol•l Colt 01 2023 Adilions 3.552 3.SS2 31 Il•r¢h 2024 3.552 3.552 Depreclatlon 01 ￿rit 2023 Charge for the year 3.071 243 3.071 243 31 Alar¢h 2024 3.314 3.314 N•t book v•1 31 March 2024 238 230 01 WI 2023 401 481 24 Ocular Melanoma UK Notes lo the Accounts for the year ¢nd¢d 31 March 2025 11 Stocks & Work in Proprus 2025 2024 Stoths befoTe wnte d¢Nr 2.108 2,108 12 Debtors 2025 2024 Trade dobiors 22.884 22,884 13 Cr•dltor8.' amounts lalllng wlthln on• y••r 2026 2024 Trade creditor5 cnja 776 1,738 1.604 14 Incom• and Exp•ndSiur• account •ummary 2025 2024 At 1 Aprll 2024 Surp￿$ after tax lor y¢or 78.015 7.442 78,703 16881 At 31 M•r¢h 2025 85.457 78.015 15 No r•latgd ￿rtY transaetlom No tNst¢• or ot￿r person r•L•ted lo th¢ Chaity h•J arry pbrnoml int•r•si •ny contracl or tr•rysKtsoTh •nt¢red into by the charity duriThJ the year. 16 P•rtl¢ularn of how yrtlcular funds ar• r•pr•s?nted by 4s•ets •nd li•blllll¢• At 31 March 2025 lknwvdlrfct•d D••19Nt•d Iwd• Rtsiwl¢hd lund• Tot•1 Fun Taryibk• Flxed Assets CurrentA83ets Curtyit LIab￿l￿e8 60.189 11.7361 26.908 87.097 11.7361 S8,$49 26.908 85.457 At 1 Awll 2024 D•#i4n•hd nds R•*lrtcl•d Tot41 Fund$ Tarvjibk Fixed Assets Cuffenl Assets Currenl Liabrfib"e$ 238 42.774 1.6041 238 79,381 11,6041 36,607 41A08 36,607 78,015 25 Ocular Melanoma UK Notss to the Accounts for the year ended 31 March 2025 17 Chang¢ in totsl fvnds owr thè y•ar as shown In Not• 16 . anatysed by Individual funds Funth bri￿9￿ MO￿￿*nI In Tr•nbl•rs lorw•rd Irorn In 2025 b•tsw•n 2024 lunth Irt 1025 Pund• c4rrl•d fonnrd to 202$ UnT•strIct•d•ndd•slw￿ffUn￿9... Llnre8tnct8d Re¥enu• Funds 41.408 17.141 $8,549 Total Urntrl¢t•d •nd dMl9n•i•d furrfl• 41.401 68,$49 R•sirl¢i•dlunds.'. Annual Conf¢ien¢• P•1￿￿1 fokler Patwnl Infonnalim to prffKk 8taTrJard R•$our¢4s HCP Trial Databa Helpline Advisor Rele aThJ S Py$¢hologi¢al Support Educational Ev•ni 7.167 3.675 1.883 2.333 2.333 10.544 4.839 3.833 16.6671 soo 3.675 1,710 11731 1,768 125 18.C691 817 2,458 4,47S 5,656 4.333 Tot•1 r••trfj¢t•d fvnds 9,699 26,908 Total charlty l￿d5 78.015 7.442 85.457 18 An•ly81• of movements In fund• th• y••r *• •hown In Not• 17 ol￿r GBlnB & MLw•m•Dt I In¢om• Exp•ndllur• 202• 2025 2026 Unrestrlctvd•ndd•slgn•t•d fvn￿... Unresiricled Revenue Funds 111.019 193,8781 17,141 Conl•r*nce P￿t￿nI fokl•f pat￿nI InfoimatKn 10 itaThJwd Retsourtes HCP Tri81 Database Helpline Advisor Role ar¥J SLWrt F¥seh¢l)gical Support Educational Event 24.349 131.0161 16,667) 16.7fy) 118.8731 11731 1.768 12S 16.0891 817 11.7751 120.1041 19.6631 14.035 10.5(KI 173.461 7.442 26 Ocular Melanoma UK Notes to the Accounts foi the year ended 31 Ma￿h 2025 19 The purpos•s for which the funds as Unresirict8danddeslgrtated funtts... These lunds aTe lor the ￿￿et*[￿j Ihe otpctives of the chanty. Io provth reser%e$ lor future acb¥itse5, arnl. $￿'ecI lo tharity *i$labon, are ￿￿e fr£￿ am restrKbttlS on their use. Unre$trided Re¥enu8 FuTrJs R•strlct•d lunds.". Restricted fvnd5 are funds that donors have 9i%*n for a particuLqi purpwe an￿1* kY¢4e¢l os outtined by donors and may indude other ¢th1￿Cled cost5. ain and use of eath restricted fund are delaikd In the notes ol tho fiMn¢AI st8t•ments. Restricted R•v•nu• Funds 20 Ultimat• controlllng paty The charty Is under the Contr￿ of 115 Wl ftwnbers. Every member of the chafity ￿ obliged lo cOn1n￿rt& $u¢h wnounl Bs may be required exc••d*rs E10 10 lh• a&68t8 of the company in Ihe ol its beiThJ wound up he Th she 15 a rn￿￿r. or within om y•¥r oftei hg or 8he c••s•$ lo t¢ • m•mL*r. 27 Ocular Melanoma UK Détailed analysis of In¢om• and expenditur8 for tho yèar •nded 31 March 2025 as r¢quired by the SORP 201$ This analysls 1$ classsified by ¢onv•ntional nominal descriplions andnol by activlty. 21 Donations. Grants and Legacles Currort y••f Curr•nt y•¥r IknT•SWlct•d R•*id¢t•d Fun Furb Current y••r Tothi FuThd¥ Prfor Y¢ar Totsl Fund* 202S 2015 2025 2024 Small ¢Jonations individually less than £1(KN) 8rK)nYrThj￿ do￿)￿& 30.057 30.057 2,943 21.996 2.329 CLS UK 1.000 In Merr lo.8￿ 10.802 13.786 Totsl donatlons glfts from Indlvldualx 39,111 43.802 43.802 Oonatlonl and 9fft• Irom Indl*4bdu•l• IlrKlud• HMRC rnlund• on offt ¥ld•d don•tlon•l. Prfor Y•ar anal￿￿• Prtor Y•*r PrtQF Y••r lknr•*tri¢t•d R•¥tdei•d FundB Fund• Prf•rY••r 70ts1 Fur 2024 2024 2024 Prlor year 39,111 Cury•nt )wr Currnni y•Av Cuvr•rt yMr Toi•l Fun Prlor Y•*r Tot41 Fund¥ 2025 2025 242S 2024 L•gocS0• f•ulvabl• IMJH 10,C 10.000 Tot•1 legach• rK•l¥•bl• 10,IIIKI 10,IXIO L•gacl•• r•c•lvabh. Prfor Ygar anal￿1¥ PrforY••r Pflor Y••r UmM•irl¢t•d R•stri¢t•d Fur Prlor Y•ar T•tal Fun 2024 2OZ4 2024 Prlor y•ar 28 Ocular Melanoma UK Detslled analysi$ of Income and expenditure for the year ended 31 March 2025 as required by the SORP 2015 Revenue grants •nddon•tths from non wblk bodi•s Cyrrerrt ye•r Curr•nt yw currnnt year Prfor Y•ar Lkntrkt•d R•sth¢W Taial Fund¥ Toiol Fund• 2025 2025 2025 2024 Dekalh Sy7lems Ltd 15,000 15,1100 11.(KKI 1nynur￿Or6 LSmfted 32,C(#) 32,000 32,C Aura B￿Se1£11t1$ 22.884 22.884 sion FOundat￿n Alan eoswell C￿ty AIA 3,022 Souttr Charil801• Tfusl TriS8lus Lrfe Soen¢• Ideaya BK)sc￿￿eS Total prl¥Jt• wctor r•v•nu• grant• 69,884 72.384 64.022 R•¥enw grant• and don•tlon• from non publlc t￿1•4 Ilndud• Glft Ald donth• Irom •ub•ldl•rb••l Y•ar anal￿1• Prlor Prfov Yw UnrMlvlct•d R•iid¢i•d Fw Prf¢v Y• Prlor Yvr T￿thI Fund• 2024 2024 2024 Prfor Y•ar 3.022 61.LK(I 64,022 29 Ocular Melanoma UK Detailed analysis of in¢om• and expenditure for the yèar ended 31 March 2025 as rèquirod by th• SORP 2015 Total Donations. Grants and Legacies Unro5trict•d Restri¢trd Current Y•Jr Fund Toi¥l Funds Pr4ty Y••r Tolal Funds Current yw 2025 2025 202$ 2024 Total Donations, Gr•nts and Looaci A1 56,302 126.186 103,133 Unrestrktad R•Stri￿d Fun Funth 2024 2024 Priory••r Tothl Fun 2024 Total Donatlons, Grants and Leqacl•8 A1 42.133 61,000 103.133 22 Incom• from charltsbl• a¢tlvltl•s- Tradlng A¢tlvltl•s Curr•nt y•¥r ywr Cmnt y••w R•strlGt•d Fund¥ ¢urr•nt y•ar Tothi Prlor Year To¢•1 Funth 2025 2025 2025 2024 Prlmary purpo•• •nd •nclll•ry trodlng Sale of goods and servicw in accordw with the charills objects 247 247 325 Total Prlm•ry purpov and anelll•ry tr*Jlny 247 247 325 prtorye*r prtar Y••r Unrwtrtcwd R•strl¢t•d Fund¢ 2024 Pvlor Yur Tcéal Fun 2024 2024 Prlmary purpoJ• and *neIl1￿ tradlng Sala of goods a￿1 seNces in acejjr wilh ttte eharitls objects 325 325 Total Prlmory purpoa• and anclllary trathrvJ 325 325 Ocular Melanoma UK Detailed analysis of income and expenditur• for the yoar ond•d 31 March 2025 as required by the SORP 2015 23 TO￿ Incrrtne from ¢harl¢abl? xtl¥ill•s Cvrrent ￿*r Currnnt year curr*￿ IinreslVlCted ￿0#￿¢1•0 TWI F¥n4ts Fur Funds Prlor Y•ar CutrTrnl y¢or Total Ftsnds 202S 2025 2025 2024 Total from charila￿e traJiryJ 247 247 325 Total fr¢)m eharftabl• a¢￿¥51￿* 247 247 325 In¢om• from ¢h¥rl¢obkn ocllvltS0*. Prlor Year anal￿* Prlor Yur Pdor Y•*r Prlor yvar Fun Total Fund¥ 24 2024 Tol81 income Irom c￿•￿e tr8dir 325 325 325 325 31 O¢ular Melanoma UK Dgtailgd analysis of incom• and •xp•nditure for the year ended 31 March 2025 as re9uired by the SORP 2015 24 Income from othèr. non charltsbl¢. trading activities Curmty••t Cwr•rtt Curr•nt year Llnr•stnc* *(esthcted Tot•1 Fund* Prtor Y••f Totsl Fund5 2025 2025 2024 I1￿me l¥om fur￿181$1￿ events 53.531 53,531 45,317 Total fr<)m othor a¢tl¥lll•• 51531 53.531 45.317 Income from othgr. non charltabl•. tra￿￿9 •ctlvitSes. Prfor Y￿r Fun Furb Y4)tsl Fthi Pylor Y•af 45.317 45,317 Ocular Melanoma UK Detailèd analysi$ of In¢ome and expenditure for th8 ￿ar •nd•d 31 March 2025 as required by the SORP 2015 25 Expendlture on charitable activities - Dlre¢t Syndlng Curyeftt yè•r Current y•ar Currwt ￿r Prtor Y•ai Total Funth Totsl Fund Curr•nt Year Funth Furbds 2025 2025 2025 2024 Gross w4e5 arKI s8laries. charilat40 59.777 23,1Ck8 2.885 97.851 Defined conlritwtKJn costs - charitable activities Travd 8Th1 St*>slstenc•. Chalita￿+ Activities Markeliro and adv•li5irvJ of ¢harilable sarviess Charitsbb acliwtKes cosls Staff welfare 2,429 3.886 2.828 747 3.918 S.250 2.253 261 52.475 54.728 261 26,706 Total dlr•ct sp•nding 824 71,466 76.915 148,381 129,308 All thè èxpethlrtu￿ in the pr￿ year was unrestrict•d. Yw Prl•r Y••r Pvlor Ymr Tot•1 Fundi Prlor Y￿r Fun 2024 2024 2024 Gross w4•s aThJ $alrn. atliviliès Defin￿ ¢onlributK)n FertJth costs charitable a¢liwlles Travel and Subsister￿e- Chadt8bl Activit￿8 MarkgtiThJ and thertisiTrJ ol chantaNe seNices c￿ritable 8Cti¥riti95 costs 66.951 97.851 747 747 118 1.395 25,311 26.708 Total dlre¢t sp•ndlng 82a 73.097 56,211 129.308 33 Ocular M•lanoma UK D¢talled analysis of incom• and expendlture l¢r th¢ •nded 31 March 2025 as required by the SORP 2015 26 Support costs for ¢haritsblè activities Cutt•fit y•ar Curr•nt y••r Current year Pflly Y••r Total Funth Total Fund¥ Curronl Year Funds Funds 2025 2025 2025 2024 Employee cost5 not includedin dir•cl Costs Recruitmenl expenses Adminlstrativ• ov•rh••ds Taepho￿. lax and intemel Slalionery ènd prinlir#J m8mL￿rshiP su￿rI1p¢￿8 Sthrfare Iicences aThJ 4xpgn SuThYry expenMs In$uran¢e 256 1.788 1.949 257 2.959 5,308 32 1.019 1.885 597 2.662 2,682 257 2.959 32 1.019 907 Prol•$slonal loes pald to a¢fvl$ors other than audltoror •x•mlner Aceounlancy fees other than èxaminaiitsn or a￿lit fees 952 Other legal aTrJ wlessh)nal 1.832 1,772 3,484 5.363 Flnanclal cosls 8ank charges Deyeu'8lK)n & ArTr)rtiSa1￿ in total for I perkmj 97 132 142 142 243 Support co•t• b•lor• r••llo¢atlon 14,411 17.079 16.499 Totsl 8upp¢rt Costs- Curr•nt Y••r 14.411 17.079 16.499 The ba6+s of allocal¥)n tsf tsjsts ￿ts￿tIeS i8 descriw accoun￿Tr3 [X)I￿1•S All Ihe expe￿il￿e in th8 prior was unrestr1d￿. 27 Other Exp•ndltur•- Gov•rnance ¢osts Currotyt y••r Currerrt ￿•T Curr•nl y••r Tothi Funds p￿or Y••r Total Funds Curr•nl Y••r Fur 2025 2025 2025 2024 IndgpeTrJenl Examiners le8S 1,224 1.170 Total G0￿Man¢• 1.224 1.170 All the expenditure In thè wjr y8ar wa¥ ￿￿trict￿. Ocular Melanorna UK Detailed analysis of incom• and expenditure for t￿ y•a¥ •nd•d 31 March 2025 as required by the SORP 2015 28 Total Charitabl8 gxwndfture y••r Curr•nt year Curr•rrt y••r Prlw Y••1 TfA•I Fun Total Funds Currnnt Y•Ar Furbth Funds 2025 2025 202S 2024 Total dir£d spendiry Totsl ¢harilable Iradir¥J costs Tolal suFwrt C051s Total Govemance costs 82a B2b 82d B28 71.466 76.915 148.381 129,308 14,411 1.224 17.079 1.224 16.499 1,170 Total charltabl• ¢xp•ndltur• 07.101 79,583 166.684 147,011 prtoryw Pvlw Y••r Pdor Y• Prior Y•ar Fund• 3024 2024 Total direct spendirq Totsl charitst4e Iradirva costs Tolal suppjrt costs Toial Go¥em8nce costs 82a B2b 82d B2• 73.097 56.211 129.308 16.499 16.499 1.170 Total ch#rltabl• •xp•ndltvr• 56,211 147.011 29 EXp0ndl￿r4 on ral•Sn9 funds and cosls ol Investment management Cyrr•Trt y••r Curr•nt yew Curt•rt y•w Y••f vnrmtricth T4x•I Funds Tot•1 Fun Current Y•ar 2025 2025 2025 2024 Cost oi fuThJraisirKJ actiwties 6.777 0.777 2.972 Tolal fundra1￿￿ C￿1# All the expenditure in the wor yèw was unreslrKl&J. B1 6,TT7 6.777 2,972 35